Determination of the two major endocannabinoids in human plasma by μ-SPE followed by HPLC-MS/MS

[1]  D. Tsikas,et al.  Simultaneous UPLC-MS/MS quantification of the endocannabinoids 2-arachidonoyl glycerol (2AG), 1-arachidonoyl glycerol (1AG), and anandamide in human plasma: minimization of matrix-effects, 2AG/1AG isomerization and degradation by toluene solvent extraction. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  D. Tsikas,et al.  Quantification of endocannabinoids in biological systems by chromatography and mass spectrometry: a comprehensive review from an analytical and biological perspective. , 2011, Biochimica et biophysica acta.

[3]  B. Gorzalka,et al.  Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[4]  P. Hyytiä,et al.  Determination of endocannabinoids in nematodes and human brain tissue by liquid chromatography electrospray ionization tandem mass spectrometry. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  R. Curini,et al.  Determination of Illicit Drugs in Urine and Plasma by Micro-SPE Followed by HPLC–MS/MS , 2011, Chromatographia.

[6]  A. Amoako,et al.  Quantitative analysis of anandamide and related acylethanolamides in human seminal plasma by ultra performance liquid chromatography tandem mass spectrometry. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  E. Dainese,et al.  Intracellular trafficking of anandamide: new concepts for signaling. , 2010, Trends in biochemical sciences.

[8]  Roberta Risoluti,et al.  Micro-solid phase extraction coupled with high-performance liquid chromatography-tandem mass spectrometry for the determination of stimulants, hallucinogens, ketamine and phencyclidine in oral fluids. , 2010, Analytica chimica acta.

[9]  Hao Wang,et al.  Validation and application of an LC-MS/MS method for quantitation of three fatty acid ethanolamides as biomarkers for fatty acid hydrolase inhibition in human plasma. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[10]  V. D. M. A. L. D. Petrocellis.  Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. , 2010 .

[11]  P. Chanda,et al.  Simultaneous determination of 2-arachidonoylglycerol, 1-arachidonoylglycerol and arachidonic acid in mouse brain tissue using liquid chromatography/tandem mass spectrometry. , 2010, Journal of mass spectrometry : JMS.

[12]  B. Barroso,et al.  Simultaneous quantitative analysis of N-acylethanolamides in clinical samples. , 2009, Analytical biochemistry.

[13]  M. Maccarrone.  Endocannabinoids: friends and foes of reproduction. , 2009, Progress in lipid research.

[14]  M. Nagarkatti,et al.  Endocannabinoids and immune regulation. , 2009, Pharmacological research.

[15]  J. Ozer,et al.  Endogenous ethanolamide analysis in human plasma using HPLC tandem MS with electrospray ionization. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[16]  M. García,et al.  Enhancement of the hypotensive effects of intrathecally injected endocannabinoids by the entourage compound palmitoylethanolamide. , 2009, European journal of pharmacology.

[17]  K. Verhoeckx,et al.  Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography-tandem mass spectrometry. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[18]  Aurélien Thomas,et al.  Quantitative and qualitative profiling of endocannabinoids in human plasma using a triple quadrupole linear ion trap mass spectrometer with liquid chromatography. , 2009, Rapid communications in mass spectrometry : RCM.

[19]  L. Petrocellis,et al.  An introduction to the endocannabinoid system: from the early to the latest concepts , 2009 .

[20]  A. Taylor,et al.  A solid-phase method for the extraction and measurement of anandamide from multiple human biomatrices. , 2009, Analytical biochemistry.

[21]  D. Barrett,et al.  ‘Entourage’ effects of N‐palmitoylethanolamide and N‐oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors , 2008, British journal of pharmacology.

[22]  A. Taylor,et al.  Ultra performance liquid chromatography tandem mass spectrometry method for the measurement of anandamide in human plasma. , 2008, Analytical biochemistry.

[23]  J. Klosterkötter,et al.  Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. , 2007, Analytical biochemistry.

[24]  K. Mackie,et al.  The emerging functions of endocannabinoid signaling during CNS development. , 2007, Trends in pharmacological sciences.

[25]  Olaf H Drummer,et al.  Validation of new methods. , 2007, Forensic science international.

[26]  D. Barrett,et al.  Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. , 2007, Analytical biochemistry.

[27]  G. Schelling,et al.  Pitfalls in measuring the endocannabinoid 2-arachidonoyl glycerol in biological samples , 2007, Clinical chemistry and laboratory medicine.

[28]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[29]  M. Maj,et al.  Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. , 2006, The Journal of clinical endocrinology and metabolism.

[30]  M. Maj,et al.  Blood Levels of the Endocannabinoid Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in Bulimia Nervosa , 2005, Neuropsychopharmacology.

[31]  A. Giuffrida,et al.  Cannabimimetic Effects of Osteopathic Manipulative Treatment , 2005, The Journal of the American Osteopathic Association.

[32]  V. Marzo,et al.  Endocannabinoid control of food intake and energy balance , 2005, Nature Neuroscience.

[33]  Y. Tanifuji,et al.  Simultaneous determination of endocannabinoids (arachidonylethanolamide and 2-arachidonylglycerol) and isoprostane (8-epiprostaglandin F2alpha) by gas chromatography-mass spectrometry-selected ion monitoring for medical samples. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[34]  B. Incledon,et al.  Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography-tandem mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[35]  L. Marnett,et al.  Chemical stability of 2-arachidonylglycerol under biological conditions. , 2002, Chemistry and physics of lipids.

[36]  F. Bymaster,et al.  Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. , 2002, The Journal of pharmacology and experimental therapeutics.

[37]  Z. Vogel,et al.  2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Maccarrone,et al.  Gas chromatography–mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture , 2001, Journal of neurochemistry.

[39]  L. Petrocellis,et al.  N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. , 2000, The Biochemical journal.

[40]  D. Piomelli,et al.  Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. , 2000, Analytical biochemistry.

[41]  M. Palkovits,et al.  Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat , 1996, FEBS letters.

[42]  P. C. Schmid,et al.  Occurrence and postmortem generation of anandamide and other long‐chain N‐acylethanolamines in mammalian brain , 1995, FEBS letters.

[43]  A. Yamashita,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.

[44]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[45]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.